Cancer-associated epitope

An epitope and adenocarcinoma technology, applied in the translation products of oncogenes, anti-receptors/cell surface antigens/cell surface determinant immunoglobulins, drug combinations, etc., can solve problems such as lack of filament elongation
CN1639185AInactive Publication Date: 2005-07-13THE SCRIPPS RES INST
23 Cites 13 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
THE SCRIPPS RES INST
Publication Date
2005-07-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention provides a cancer-associated epitope consisting of two polypeptides, wherein the first polypeptide is derived from cytokeratin K8, and the second polypeptide is derived from cytokeratin K18. The cancer-associated epitopes become exposed during malignant transformation, especially in colon, breast, ovarian, kidney, lung and testicular tissues. Exposure of the cancer-associated epitopes occurs by cleavage and removal of the N-terminal peptides of cytokeratins K8 and K18. The invention also provides a cancer-associated epitope up to 10M-1 in cancer tissue, which is 100 times higher than that of cytokeratin K8 / K18 complex in normal tissue. The present invention provides cancer-associated epitopes, binding entities, antibodies and methods for detecting and treating cancer using the epitopes, binding entities and antibodies.
Need to check novelty before this filing date? Find Prior Art

Description

Invention field

[0001] The present invention relates to cancer-related epitopes, antibodies and polypeptide binding entities directed against the epitopes. The present invention also relates to a diagnostic reagent including the epitope, antibody or binding entity, and relates to the use of the epitope, antibody or binding entity for various diagnostic or therapeutic purposes. The present invention also relates to a pharmaceutical composition comprising an epitope, antibody or binding entity. Background of the invention

[0002] Malignant tumors sometimes express unique antigens or "markers" that provide a means for detecting and possibly treating the cancer. For example, antigens unique to the tumor can be purified and prepared, and used to prepare antibodies. The antibody produced by the antigen can be used as a detection tool for monitoring the level of tumor markers in the host, so as to track the progress of the disease or the effect of treatment. Link a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More